Mitigation Strategies for US and EU Supply Chain Risk Introduced by the COVID-19 Pandemic

The current global health crisis has a profound effect on the pharmaceutical supply chain, from raw materials to clinical supply, to store shelves. This 30-minute talk and Q&A summarized the FDA and EMA recommendations and guidance regarding these challenges and provided our perspective on industry approaches.

View-On-Demand-Button.png

Title: Mitigation Strategies for US and EU Supply Chain Risk Introduced by the COVID-19 Pandemic

Contributors

THUMB-James.png
 James Zoshak, Associate Principal Regulatory Writer, Certara


THUMB_Terry.png
 Terrance (Terry) Ocheltree, Ph.D., R.Ph., Vice President, Regulatory Strategy and CMC, Certara


THUMB_Renata.png
 Renata Lavach-Savy, Associate Principal Regulatory Writer, Certara


THUMB_Rob.png
 Robert Waterland, Ph.D., Associate Principal Regulatory Writer, Certara

Follow Us:

Additional text can go here...

MENU